系统性红斑狼疮女性的宫颈癌筛查现状
基于2001至2014年MarketScan商业索赔数据库,纳入4,316例初诊系统性红斑狼疮(SLE)女性,评估3年内宫颈癌筛查率及相关异常结果。SLE患者筛查率高于一般对照(73.4%对58.5%,P<0.001),但超过25%未筛查且筛查率随时间下降;异常病理结果索赔在SLE中更常见(12.3%对9.8%,P<0.001)。
要点
- SLE女性宫颈癌筛查率高于一般对照,但仍有超过25%未筛查。
- 近期年份、高龄、高共病评分、糖皮质激素及免疫抑制剂使用与筛查率降低相关。
- SLE女性异常宫颈病理结果索赔率高于对照,支持定期筛查。
核心结论
- SLE女性宫颈癌筛查率虽高于一般对照,但超过25%未筛查且筛查率似随时间下降。
- SLE女性异常宫颈筛查结果风险高于对照,支持定期筛查的必要性。
研究设计与样本
- 基于MarketScan商业索赔与 encounters 数据库2001至2014年数据的回顾性队列研究。
- 纳入4,316例初诊SLE女性,评估初诊后3年内宫颈癌筛查率及相关诊断索赔。
- 采用多变量logistic回归评估筛查与狼疮治疗的相关性,并进行年龄匹配无结缔组织病女性的匹配logistic回归比较。
主要发现
- SLE女性筛查率73.4%,一般对照58.5%(P<0.001)。
- 与筛查率降低相关的因素包括:2012-2014年较2001-2005年(OR 0.70,95%CI 0.55-0.89)、年龄≥61岁(OR 0.27,95%CI 0.18-0.39)、共病评分≥2(OR 0.71,95%CI 0.6-0.83)、使用糖皮质激素(OR 0.77,95%CI 0.61-0.97)、使用免疫抑制剂(OR 0.80,95%CI 0.69-0.94)。
- SLE女性异常病理结果索赔率12.3%,一般对照9.8%(P<0.001)。
临床怎么用
- 对SLE女性应定期进行宫颈癌筛查,尤其关注高龄、高共病评分及使用糖皮质激素或免疫抑制剂者。
- 尽管SLE筛查率高于一般人群,仍需注意超过25%未筛查及筛查率下降的趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine rates of cervical cancer screening and associated abnormal results in women with systemic lupus erythematosus (SLE). METHODS: We identified women with an initial diagnosis of SLE in the MarketScan Commercial Claims and Encounters Database from 2001 to 2014. Cervical cancer screening rates and associated diagnostic claims within 3 years of the initial claim were determined. Multivariable logistic regression was performed to evaluate the association of screening with lupus treatment. A matched logistic regression analysis was conducted to compare screening rates to those in age-matched women without connective tissue disease. RESULTS: We included 4,316 women with SLE. Screening rates were higher in women with SLE than in general controls (73.4% versus 58.5%; P < 0.001). Factors associated with decreased screening included recent time (odds ratio [OR] 0.70 [95% confidence interval (95% CI)] 0.55-0.89) (2012-2014 compared to 2001-2005), age ≥61 years (OR 0.27 [95% CI 0.18-0.39]), comorbidity score ≥2 (OR 0.71 [95% CI 0.6-0.83]), corticosteroid use (OR 0.77 [95% CI 0.61-0.97]), and use of immunosuppressants (OR 0.80 [95% CI 0.69-0.94]). Abnormal pathology result claims were more common in women with SLE than in general controls (12.3% versus 9.8%; P < 0.001). CONCLUSION: Though with higher rates than the general cohort, over 25% of the patients with SLE were not screened, and screening rates seem to be decreasing over time. Patients with SLE are at higher risk of abnormal cervical screening test results than controls, supporting the need for regular screening.
引用
- Bruera S, Lei X, Zogala R, et al. Cervical Cancer Screening in Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2021. PMID: 32799430. doi:10.1002/acr.24414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。